Erythropoietin in bone – Controversies and consensus

Sahar Hiram-Bab, Drorit Neumann, Yankel Gabet*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations

Abstract

Erythropoietin (Epo) is the main hormone that regulates the production of red blood cells (hematopoiesis), by stimulating their progenitors. Beyond this vital function, several emerging roles have been noted for Epo in other tissues, including neurons, heart and retina. The skeletal system is also affected by Epo, however, its actions on bone are, as yet, controversial. Here, we review the seemingly contradicting evidence regarding Epo effects on bone remodeling. We also discuss the evidence pointing to a direct versus indirect effect of Epo on the osteoblastic and osteoclastic cell lineages. The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling. Differences in conclusions from the published in-vitro studies may thus relate to the different experimental conditions. Taken together, these studies indicate a complexity of Epo functions in bone cells.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalCytokine
Volume89
DOIs
StatePublished - 1 Jan 2017

Keywords

  • Bone homeostasis
  • Bone regeneration
  • Erythropoietin
  • Macrophages
  • Osteoblasts
  • Osteoclastogenesis

Fingerprint

Dive into the research topics of 'Erythropoietin in bone – Controversies and consensus'. Together they form a unique fingerprint.

Cite this